Predeposit Autologous Blood Transfusion Research Articles

Indications and organisational methods for autologous blood transfusion procedures in Italy: results of a national survey.

Pre-operative donation of autologous blood is a practice that is now being abandoned. Alternative methods of transfusing autologous blood, other than predeposited blood, do however play a role in limiting the need for transfusion of allogeneic blood. This survey of autologous blood transfusion practices, promoted by the Italian Society of Transfusion Medicine and Immunohaematology more than 2 years after the publication of national recommendations on the subject, was intended to acquire information on the indications for predeposit in Italy and on some organisational aspects of the alternative techniques of autotransfusion. A structured questionnaire consisting of 22 questions on the indications and organisational methods of autologous blood transfusion was made available on a web platform from 15 January to 15 March, 2013. The 232 Transfusion Services in Italy were invited by e-mail to complete the online survey. Of the 232 transfusion structures contacted, 160 (69%) responded to the survey, with the response rate decreasing from the North towards the South and the Islands. The use of predeposit has decreased considerably in Italy and about 50% of the units collected are discarded because of lack of use. Alternative techniques (acute isovolaemic haemodilution and peri-operative blood salvage) are used at different frequencies across the country. The data collected in this survey can be considered representative of national practice; they show that the already very limited indications for predeposit autologous blood transfusion must be adhered to even more scrupulously, also to avoid the notable waste of resources due to unused units.Users of alternative autotransfusion techniques must be involved in order to gain a full picture of the degree of use of such techniques; multidisciplinary agreement on the indications for their use is essential in order for these indications to have an effective role in "patient blood management" programmes.

Predeposit autologous blood transfusion: Do we require to promote it?

Introduction: Safest blood a patient can receive is his own. Quest for safe blood transfusion has remained of prime concern. To meet this aspiration, various forms of autologous blood transfusions can be practiced. It is especially suitable for patients with rare blood groups and religious sects such as Jehovah's witness autologous transfusion is extremely safe. Cross matching is not required; iso-immunization to a foreign body is excluded. Fear of transfusion transmissible disease can be ignored. Therefore, autologous blood transfusion is required to be revisited. Materials and Methods: This is a prospective study carried out at Padmashree Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune between July 2010 and May 2012. Study comprised of 100 patients divided into two groups, autologous and homologous. Benefits of autologous transfusion were studied. Results: There was no significant change in hematocrit and blood parameters after blood donation. That is mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration (P < 0.001) after blood donation. Only one complication of vasovagal syncope was observed at the time of blood donation. Conclusion: Autologous blood transfusion is safe. Easy alternative to be practiced in elective surgeries, especially in patients with rare blood group or believers of Jehovah's witness faith. It helps to reduce the shortfall in national blood inventory. Autologous blood donation should be practiced whenever possible.

BCSH guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion, August 2006 ‐ Reply from the Chairman of the BCSH Transfusion Task Force

Transfusion MedicineVolume 17, Issue 5 p. 366-366 BCSH guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion, August 2006 - Reply from the Chairman of the BCSH Transfusion Task Force F. Boulton, Corresponding Author F. Boulton National Blood Service, Southampton, UKFrank Boulton, British Committee for Standards in Haematology, 100 White Lion Street, London N1 9PF, UK.e-mail: frank.boulton@gmail.com, frank.boulton@nbs.nhs.ukSearch for more papers by this author F. Boulton, Corresponding Author F. Boulton National Blood Service, Southampton, UKFrank Boulton, British Committee for Standards in Haematology, 100 White Lion Street, London N1 9PF, UK.e-mail: frank.boulton@gmail.com, frank.boulton@nbs.nhs.ukSearch for more papers by this author First published: 27 September 2007 https://doi.org/10.1111/j.1365-3148.2007.00753.xCitations: 12Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume17, Issue5October 2007Pages 366-366 RelatedInformation

BCSH guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion, August 2006

BCSH guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion, August 2006

Predeposit autologous blood transfusion in patients with colorectal cancer: A feasibility study

Over a 2-year period, a predeposit autologous blood transfusion service was provided for all patients undergoing elective surgery for left-sided colonic or rectal cancer in one hospital. Of 129 such patients, 28 were suitable for autologous donation. Eight of these received autologous blood only, 13 required no transfusion, and seven needed additional homologous blood. Thus, although predeposit autologous transfusion for patients with colorectal cancer is possible, only a very small proportion are likely to derive any benefit which it might confer.

Predeposit autologous blood transfusion in a tropical surgical practice.

Predeposit autologous blood transfusion in a tropical surgical practice.

秋田県輸血療法委員会合同会議による地域における適正輸血推進への取り組み

Guidelines for blood transfusion require that a transfusion committee should be established in each hospital to ensure proper blood transfusion. In 1998, Akita Prefecture, Akita Red Cross Blood Center and several major hospitals organized a joint meeting of transfusion committees of Akita Prefecture. This paper introduces the Joint Meeting of Transfusion Committees, and discusses its influence on proper blood usage. The Joint Meeting of Transfusion Committee has been held once a year since 1998 and consists of a special lecture, questionnaire analysis reports, and discussion of specific topics. Among results of a survey conducted in 2001, transfusion committees were established in 30 hospitals and blood transfusion service was established in 8 of a total of 46 hospitals. During a 6-month period (January 2001 to June 2001), red cells were transfused to 3, 046 patients, plasma was transfused to 739 patients and platelets were transfused to 518 patients in 46 hospitals, representing almost the classified total usage of blood in Akita Prefecture. The status of autologous blood transfusion in Akita Prefecture was also by the survey. However, differences in the status of predeposit autologous blood transfusion were significant among hospitals. The Joint Meeting of Transfusion Committees in Akita Prefecture provides a good opportunity for the exchange of information and education for hospitals. The Joint Meeting is also useful in promoting the establishment of blood transfusion services and activating transfusion committees in hospitals.

貯血式自己血輸血の現状 日本輸血学会認定施設における検討 自己血輸血の採血，管理，実施状況について 輸血学会自己血輸血小委員会報告 １

In 1999, the Japan Society of Blood Transfusion organized a small committee on autologous blood transfusion. The committee was assigned to evaluate the status of predeposit autologous blood transfusion in hospitals approved by the Japan Society of Blood Transfusion and to clarify problems concerning the promotion of autologous blood transfusion. Questionnaires were sent to 86 hospitals. Information on each hospital (number of beds, number of doctors and medical technologists approved by the Society, etc), establishment of blood transfusion service, preservation methods, and management and compatibility testing of autologous blood were evaluated. In addition, number of cases and units of autologous blood transfusion from. Jan 1999 to Dec 1999 and status of homologous blood transfusion during operation were analyzed. Predeposit autologous blood transfusion was performed in all 68 hospitals which answered the questionnaire. Blood transfusion service was established in 64 hospitals. However, the place of autologous blood collection and the personnel involved in blood collection were not centralized. Percentage of autologous blood without allogeneic blood cases in cases of blood transfusion during operation was 17% in total. Percentages among hospitals ranged from 3.6% to 76.9%. Percentage of autologous blood units in units of blood used during operation was 12% in total, and ranging from 0.5% to 77.6%. Differences in the status of predeposit autologous blood transfusion were significant among hospitals. Doctors approved by the Japan Society of Blood Transfusion should assume an important role in the promotion of autologous blood transfusion in hospitals.

貯血式自己血輸血の現状 日本輸血学会認定施設における検討 診療科別自己血輸血実施状況について 輸血学会自己血輸血小委員会報告 ２

The committee for autologous blood transfusion of the Japan Society of Blood Transfusion was assigned to evaluate the status of predeposit autologous blood transfusion in hospitals approved by the Japan Society of Blood Transfusion and to clarify problems concerning the promotion of autologous blood transfusion. Status of collection, management and compatibility testing of autologous blood transfusion have been analyzed and reported separately. Status of autologous blood transfusion at each surgical division was studied in this paper. Percentages of performance of predeposit autologous blood transfusion were 100% for orthopedics, 93% for cardiovascular surgery, 78% for general surgery, 91% for gynecology and obstetrics, 71% for neurological surgery and 95% for urology. Percentages of autologous blood without allogeneic blood cases and percentages of autologous blood units were higher in orthopedics, gynecology and obstetrics and urology divisions, but lower in cardiovascular surgery and general surgery. In cardiovascular surgery and general surgery, the differences in percentages of autologous blood without allogeneic blood cases and percentages of autologous blood units among hospitals were significant. Doctors approved by the Japan Society of Blood Transfusion and the blood transfusion service of the hospital should understand the status and information of blood transfusion during operation, and recognize their responsibility in promoting autologous blood transfusion in the surgical divisions where autologous blood transfusion is not performed sufficiently.

HOMOLOGOUS BLOOD TRANSFUSION: DO WE HAVE ANY ALTERNATIVES?

Homologous blood transfusion, despite numerous and serious transfusion associated hazards, is an important treatment modality. Transmission of infectious agents like HIV, hepatitis viruses, malaria, etc is a distinct possibility notwithstanding careful screening of the blood. Predeposit autologous blood transfusion (PABT) and per operative acute normovolemic haemodilution (ANH) are two comparatively safer, simpler and practical alternatives. Unfortunately, their potential remains unexploited. Earnest motivation efforts at PABT and ANH have paid handsome dividends in our hospital. These have now become very popular amongst surgeons as well as the patients. These techniques can be easily adapted at all hospitals to reduce the demand for homologous blood transfusion. ANH can be safely practised even in hospitals without a blood bank.

秋田県における貯血式自己血輸血の現状と問題点について

秋田県における貯血式自己血輸血の現状と問題点について

口腔悪性腫よう手術における術前貯血式および希釈式自己血輪血の適応

Predeposit autologous blood transfusion combined with recombinant human erythropoietin (r-HuEPO) has been used at our department since 1995 in patients undergoing operations for oral malignant tumors. This decision was based on studies of blood loss and homologous transfusions in past operations. In this report we discuss the indications, methods and issues of autologous blood transfusion in patients undergoing operations for oral malignant tumors.Among 88 patients who underwent operations for oral malignant tumors between 1993 and 1995, 40 had blood loss of over 600ml and 24 (60%) received homologous transfusions. We estimated the average blood loss according to the operation procedure by dividing the patients into seven groups depending on the extent of resection of the primary lesion and whether or not radical neck dissection and reconstruction were performed.Predeposit autologous blood transfusion combined with recombinant human erythropoietin (r-HuEPO) was given to 13 patients who suffered blood loss of over 600ml during operations performed 1 year since June 1995. The volume of predeposit blood ranged from 400 to 1600ml, averaging 1015ml.As for the effect of rHuEPO, five patients showed an excellent response and three showed a moderate response; the response rate was 67%(8/13). Blood loss up to 2200ml could be compensated by predeposit autologous blood transfusion of 1600ml. Therefore, predeposit autologous blood transfusion combined with r-HuEPO was considered safe and effective when used in patients who undergo operations for oral malignant tumors and have a large volume of blood loss.Based on our clinical experience, we established schedules for collection of 800, 1200, and 1600 ml of predeposit autologous blood within 6 weeks with the use of MAP preservative solution.

Use of predeposit autologous blood transfusion varies greatly

EDITOR,—As Bryan Christie points out, in the United States the use of predeposit autologous blood transfusion for certain surgical procedures such as planned orthopaedic surgery is high.1 This is not only because of increased demand by patients but also because doctors consider it prudent, for clinical as well as legal reasons, to inform eligible patients of the availability and …

Programmed autologous blood transfusion in children. Results of a national survey

To assess the development and the current practice of predeposit autologous blood transfusion (PABT) in children in France. Nationwide survey with a questionnaire. Survey conducted in January 1995, including 121 blood transfusion centres (BTC) out of which 101 replied. Initiated in 1979, PABT is practiced at present in 66% of BTC. This figure increased by 12% from 1993 to 1994. Orthopaedic surgery was the main indication. Other indications included bone marrow harvesting for allogenic transplantation. Concerning the inclusion criteria, the lower limit of age was 9 +/- 4 years and weight 26 +/- 10 kg. The youngest child was one-year-old and his body weight was 8 kg. The production of codified protocols would probably favour the development of PABT in children and increase its safety and its efficiency.

Predeposit autologous blood transfusion in patients with esophageal cancer

Since patients after a cancer operation without homologous blood transfusions are doing better than patients with these transfusions, many efforts have been made to reduce homologous transfusions. A predeposit autologous blood transfusion service was provided for patients scheduled for elective surgery for esophageal cancer. Twenty patients each donated two units of blood preoperatively. All patients were given oral iron supplementation. For one patient, the operation was cancelled. Twelve patients (60%) received only autologous blood, seven patients (35%) needed additional homologous blood. Overall, 35 units of autologous blood and 16 units of additional homologous blood were needed. All patients were very well motivated and preoperative blood donation was tolerated without complaints. Thus, predeposit autologous blood transfusion in patients with esophageal cancer is possible and homologous blood transfusion is reduced by 69%. No significant difference was noted between patients with autologous transfusions as against those with homologous transfusions as regards postoperative complications.

Clinical Value of Predeposit Autologous Blood Transfusion Stored as Liquid Blood

Clinical Value of Predeposit Autologous Blood Transfusion Stored as Liquid Blood

Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer

A considerable demand for convenient, rapid, inexpensive assays of ferritin in serum has been generated in recent years in hospital laboratories and blood banks. We describe a simple and rapid particle-enhanced turbidimetric immunoassay suitable for routine application in a Monarch 2000 centrifugal analyzer with commercially available reagents. This fully automated assay (y) requires no pretreatment of sample, and correlation with a two-step sandwich ELISA (x) is excellent (y = 1.018x + 0.397, Sy/x = 0.027). The analytical range extends from 5 to 900 micrograms/L. Intraassay imprecision (CV) ranged from 1.1% to 5% for various specimen concentrations. Interassay imprecision ranged from 2.2% for above-normal concentrations (755 micrograms/L) to 9.5% for low concentrations (39 micrograms/L). No specimen-related carryover was detected. The method has been useful in our predeposit autologous blood transfusion program for rapid assessment of iron status in patients undergoing repeated phlebotomies.

地方の県における自己血輸血の現状とその問題点について １９９２年度のアンケート調査から

The objective of this survey was to study the present status of autologous blood transfusion practice from April 1992 to March 1993 in the hospitals including small clinics without blood transfusion service in Akita prefecture. A questionnaire was sent to 146 surgical divisions of 37 hospitals with more than 50 beds in Akita prefecture.A total of 129 answers (88.4%) were collected and evaluated. Autologous blood transfusion program was performed in 42 divisions (32.6%) in total. Predeposit autologous blood transfusion was widely applied. Enforcement percentage of autologous blood transfusion was higher in cardiovascular surgery and orthopedic surgery divisions compared with other surgical divisions. No homologous blood was transfused in 76% of total cases and 46% and 82% cases in cardiovascular surgery and orthopedic surgery, respectively. Ninety four divisions (73%) answered that they are performing or planning one of various autologous blood transfusion programs in future. However, 29% of general surgery divisions have no plans to perform autologous blood transfusion. Several practical problems such as a shortage of man power or time to participate, short preservation duration of predeposit blood and unavailability of erythropoietin for the program were pointed out to perform predeposit autologous transfusion program. Cooperation by the Japan Red Cross blood center was strongly requested in autologous transfusion practice. Since the MAP autologous blood needs to be separated by centrifugation, separation and freezing of autologous blood products were specially requested to be performed by the blood center.

Prognostic Impact of Blood Transfusions on Disease-free Survival in Colorectal Carcinoma

Blood transfusions have been indicated as having an adverse effect on the prognosis of patients treated surgically for cancer. We carried out a randomized trial to investigate whether a predeposit autologous blood transfusion program improved prognosis in patients with colorectal cancer as compared to the current practice of allogeneic transfusion. This appeared not to be the case. However, the subgroup of untransfused patients had a significantly better disease-free survival compared with transfused patients; 73% and 59%, respectively (p = 0.001). We found that the risk of recurrence was significantly increased for patients transfused with allogeneic, or with autologous, or with both types of blood, compared with those patients who did not require transfusions; relative recurrence rates were 2.3 (p = 0.001), 1.8 (p = 0.044) and 2.5 (p = 0.009), respectively; these three rates did not differ significantly from each other. We conclude that it is not the blood transfusions themselves, but the circumstances that necessitate the transfusions that are the real determinants of prognosis.

Autotransfusion in urology: Control study on 59 cases

We studied the hematologic and clinical patterns of 59 patients undergoing urologic surgery who entered in a predeposit autologous blood transfusion program and of 59 controls to evaluate the feasibility and safety of the autotransfusional procedure in Urology. 174 units of autologous blood were donated (average 2.94 per pt.) with a high frequency of donation (2.6 days). No side effect or alteration of performance status was reported. We had a dramatic reduction of the need for homologous blood (2.21 units per pt.) without a significant difference of the average hemoglobin concentration between the two groups at discharge from hospital. Autotransfusion has significant advantages compared with conventional transfusion, reducing the complications correlated with homologous blood infusion as also our study demonstrated. Infact 1 post-transfusional hepatitis and 3 complications due to an alteration of coagulation were reported in the control group. The procedure resulted safe and feasible in most urologic operations that require almost two units of blood transfusion.